Sign In
Buy GRFS
$7.18
-0.100 (-1.37%)
At Close: Jun 23, 2026
US court finds enough evidence to proceed with Grifols lawsuit against Gotham City
03:15am, Friday, 30'th May 2025
A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols against short seller Gotham City Research, Grifols said in a statement on
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?
11:06am, Wednesday, 28'th May 2025
At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.
Grifols: If This Works Out, It Has Massive Upside
12:09pm, Thursday, 22'nd May 2025
Grifols offers compelling long-term upside, with potential returns exceeding 200% as the company recovers and grows earnings. Recent Q1 2025 results confirm strong operational recovery: top-line growt
GRFS or NBIX: Which Is the Better Value Stock Right Now?
12:46pm, Thursday, 15'th May 2025
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks presents investors with th
Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript
04:51pm, Monday, 12'th May 2025
Grifols, S.A. (NASDAQ:GRFS ) Q1 2025 Earnings Conference Call May 12, 2025 12:30 PM ET Company Participants Danny Segarra - VP, IR and Sustainability Nacho Abia - CEO Rahul Srinivasan - CFO Roland Wan
Grifols says on course to meet 2025 outlook as net profit triples
02:47pm, Monday, 12'th May 2025
Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said reinforced its confidence in meeting its full-year guidance.
IBL International collaborates with Grifols on advanced biomarker panels
09:29am, Tuesday, 08'th Apr 2025
MÄNNEDORF, Switzerland--(BUSINESS WIRE)--IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols,
Brookfield resumes Grifols takeover talks, El Confidencial reports
03:03am, Wednesday, 02'nd Apr 2025
Canadian investment fund Brookfield has resumed talks on a potential takeover of Spanish pharmaceuticals company Grifols four months after a previous attempt fell through, news website El Confidencial
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale
12:58pm, Thursday, 27'th Feb 2025
Grifols remains a strong long-term investment due to its leading position in the plasma industry and improving financial fundamentals, despite short-term volatility and lack of a dividend. The company
Grifols expects to boost revenue and free cash flow, shares soar
11:23am, Thursday, 27'th Feb 2025
Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 when it lost
Grifols' sales rise over 10% in 2024, above target
12:18pm, Wednesday, 26'th Feb 2025
Spanish drugmaker Grifols reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7.21 billion euros, up 10.2% from a year earlier and above its target for 7%
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
10:05am, Thursday, 13'th Feb 2025
DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching U
Blood Plasma Derivatives Market Insights and Forecast 2025-2030 - Grifols, SK Plasma, and Fusion Health Care Lead the Competition
06:07am, Thursday, 06'th Feb 2025
Rising Incidence of Hemophilia, Immunological Disorders, and the Growing Number of Surgical Procedures Worldwide is Driving Growth, at a CAGR of ~9% Rising Incidence of Hemophilia, Immunological Disor
Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease
06:00am, Tuesday, 14'th Jan 2025
BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced it h
Mason Capital complains about Grifols' transparency to Spanish regulator
10:55am, Monday, 13'th Jan 2025
U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding more transparency from the embattled pharmaceutical company Grifols.
